4.8 Article

N6-methyladenosine (m6A) is an endogenous A3 adenosine receptor ligand

Journal

MOLECULAR CELL
Volume 81, Issue 4, Pages 659-+

Publisher

CELL PRESS
DOI: 10.1016/j.molcel.2020.12.038

Keywords

-

Funding

  1. Japan Society for the Promotion of Science (JSPS) KAKENHI [18H02599, 18K19521, 20H05309, 18H02865, 17905074, 18959602, 20K18371, 17K08264]
  2. Japan Science and Technology Agency (JST) [SAKIGAKE JPMJPR1532]
  3. Exploratory Research for Advanced Technology (JST ERATO) [JPMJER2002]
  4. Japan Agency for Medical Research and Development (AMED) [J200001951, 17935694, PRIME JP18gm5910013, LEAP JP18gm0010004]
  5. Takeda Science Foundation
  6. Uehara Memorial Foundation
  7. Astellas Foundation for Research on Metabolic Disorders
  8. TUMUG
  9. Japan Medical Women's Association Foundation
  10. Grants-in-Aid for Scientific Research [18H02865, 18H02599, 20K18371, 20H05309, 18K19521] Funding Source: KAKEN

Ask authors/readers for more resources

The study identified N-6-methyladenosine (m(6)A) as a ligand for the human adenosine A3 receptor with higher affinity than unmodified adenosine. Structural modeling revealed the amino acids required for specific binding of m(6)A to the human A3 receptor and demonstrated its dynamic release in response to cytotoxic stimuli and facilitation of type I allergy in vivo. These findings suggest m(6)A as a signaling molecule capable of activating G protein-coupled receptors (GPCRs) and triggering pathophysiological responses, a previously unreported property of RNA modifications.
About 150 post-transcriptional RNA modifications have been identified in all kingdoms of life. During RNA catabolism, most modified nucleosides are resistant to degradation and are released into the extracellular space. In this study, we explored the physiological role of these extracellular modified nucleosides and found that N-6-methyladenosine (m(6)A), widely recognized as an epigenetic mark in RNA, acts as a ligand for the human adenosine A3 receptor, for which it has greater affinity than unmodified adenosine. We used structural modeling to define the amino acids required for specific binding of m(6)A to the human A3 receptor. We also demonstrated that m(6)A was dynamically released in response to cytotoxic stimuli and facilitated type I allergy in vivo. Our findings implicate m(6)A as a signaling molecule capable of activating G protein-coupled receptors (GPCRs) and triggering pathophysiological responses, a previously unreported property of RNA modifications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available